Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A | P37288 | 11/20 | 0.65 |
| ▸ | AVPR2 | P30518 | 9/20 | 0.65 |
| ▸ | CDK4 | P11802 | 1/20 | 0.41 |
| ▸ | CCND1 | P24385 | 1/20 | 0.41 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.40 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5835303 | 0.89 | AVPR1A (0.51) | AVPR1AAVPR2 | |
| SCHEMBL7108357 | 0.87 | AVPR1A (0.52) | AVPR1AAVPR2CDK4CCND1 | |
| SCHEMBL7115671 | 0.84 | AVPR2 (0.48) | AVPR1AAVPR2 | |
| SCHEMBL3554634 | 0.82 | AVPR2 (0.63) | AVPR1AAVPR2 | |
| SCHEMBL5785129 | 0.81 | AVPR2 (0.61) | AVPR1AAVPR2 | |
| SCHEMBL5836585 | 0.80 | AVPR2 (0.48) | AVPR1AAVPR2 | |
| SCHEMBL5835574 | 0.80 | TSHR (0.43) | AVPR1AAVPR2 | |
| SCHEMBL4138543 | 0.79 | AVPR1A (1.00) | AVPR1AAVPR2 | |
| SCHEMBL7109575 | 0.79 | AVPR2 (0.51) | AVPR1AAVPR2 | |
| SCHEMBL5784789 | 0.78 | AVPR2 (0.57) | AVPR1AAVPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030008863-A1 | Novel tricyclic diazepines tocolytic oxytocin receptor antagonists | WYETH | 2003-01-09 | — | — | US | claimed |
| US-20030008863-A1 | Novel tricyclic diazepines tocolytic oxytocin receptor antagonists | WYETH | 2003-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030008863-A1 | Novel tricyclic diazepines tocolytic oxytocin receptor antagonists | OXTR, OPRL1, HCRTR2 | AVPR1A 62/4885AVPR2 91/4885CDK4 494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.